A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates

Trial Details

NCT ID
NCT07299825
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • A166
Locations (sample)
  • Zhenzhou, Henan, China

Key Eligibility Criteria

  • Male or female patient ≥ 18 years and ≤ 75 years when signing the informed consent form.
  • Breast cancer patients by histopathology and/or cytology documented.
  • In the advanced or metastatic stage, having received no more than 5 lines of systemic therapy, one of which must include a HER2 ADC with a topoisom…
  • Patients must have experienced disease progression or intolerance during or after the most recent treatment prior to randomization.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →